Methysticin and 7,8-dihydromethysticin are two major kavalactones in kava extract to induce CYP1A1

Toxicological Sciences

Volumn 124, Issue 2, 2011, Pages 388-399

  Li, Yan ^a   Mei, Hu ^a   Wu, Qiangen ^a   Zhang, Suhui ^a   Fang, Jia Long ^a   Shi, Leming ^a   Guo, Lei ^a  

^a NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

Author keywords

Aryl hydrocarbon receptor; CYP1A1; Kava extract; Kavalactone; Molecular docking

Indexed keywords

7,8 DIHYDROKAWAIN; 7,8 DIHYDROMETHYSTICIN; AROMATIC HYDROCARBON RECEPTOR; CYTOCHROME P450 1A1; DEMETHOXYYANGONIN; KAVA EXTRACT; KAVALACTONE DERIVATIVE; KAWAIN; METHYSTICIN; PLANT MEDICINAL PRODUCT; UNCLASSIFIED DRUG; YANGONIN;

ANIMAL CELL; ARTICLE; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG STRUCTURE; ENZYME ACTIVITY; GENE EXPRESSION; LIGAND BINDING; MOLECULAR DOCKING; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN INTERACTION; SEQUENCE HOMOLOGY;

ANIMALS; BINDING SITES; CELL LINE, TUMOR; CELL SURVIVAL; CYTOCHROME P-450 CYP1A1; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INDUCTION; GENE EXPRESSION; KAVA; LACTONES; LIGANDS; MICE; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PLANT EXTRACTS; PROTEIN BINDING; PYRANS; PYRONES; RECEPTORS, ARYL HYDROCARBON; TRANSFECTION;

EID: 81855206221     PISSN: 10966080     EISSN: 10960929     Source Type: Journal    
DOI: 10.1093/toxsci/kfr235     Document Type: Article

References (71)

1. Anke, J., and Ramzan, I. (2004). Pharmacokinetic and pharmacodynamic drug interactions with Kava (Piper methysticum Forst. f.). J. Ethnopharmacol. 93, 153-160.
2. Backlund, M., Johansson, I., Mkrtchian, S., and Ingelman-Sundberg, M. (1997). Signal transduction-mediated activation of the aryl hydrocarbon receptor in rat hepatoma H4IIE cells. J. Biol. Chem. 272, 31755-31763.
3. Bisson, W. H., Koch, D. C., O'Donnell, E. F., Khalil, S. M., Kerkvliet, N. I., Tanguay, R. L., Abagyan, R., and Kolluri, S. K. (2009). Modeling of the aryl hydrocarbon receptor (AhR) ligand binding domain and its utility in virtual ligand screening to predict new AhR ligands. J. Med. Chem. 52, 5635-5641.
4. Bressler, R. (2005). Herb-drug interactions: Interactions between kava and prescription medications. Geriatrics 60, 24-25.
5. Bundesgesundheitsamt (1990). Monographie: Piperis methystici rhizoma (Kava-Kava Wurzelstock). [Federal Office for Medicines and Medicinal Products. Monograph: Kava-Kava], 101.
6. Chen, T., Guo, L., Zhang, L., Shi, L., Fang, H., Sun, Y., Fuscoe, J. C., and Mei, N. (2006). Gene expression profiles distinguish the carcinogenic effects of aristolochic acid in target (kidney) and non-target (liver) tissues in rats. BMC Bioinformatics 7(Suppl. 2), S20.
7. Clayton, N. P., Yoshizawa, K., Kissling, G. E., Burka, L. T., Chan, P. C., and Nyska, A. (2007). Immunohistochemical analysis of expressions of hepatic cytochrome P450 in F344 rats following oral treatment with kava extract. Exp. Toxicol. Pathol. 58, 223-236.
8. Clouatre, D. L. (2004). Kava kava: Examining new reports of toxicity. Toxicol. Lett. 150, 85-96.
9. Conney, A. H. (1982). Induction of microsomal enzymes by foreign chemicals and carcinogenesis by polycyclic aromatic hydrocarbons: G. H. A. Clowes Memorial Lecture. Cancer Res. 42, 4875-4917.
10. Coumailleau, P., Poellinger, L., Gustafsson, J. Å., and Whitelaw, M. L. (1995). Definition of a minimal domain of the dioxin receptor that is associated with Hsp90 and maintains wild type ligand binding affinity and specificity. J. Biol. Chem. 270, 25291.
11. De Smet, P. A. (1995). Health risks of herbal remedies. Drug Saf. 13, 81-93.
12. De Smet, P. A. (2004). Health risks of herbal remedies: An update. Clin. Pharmacol. Ther. 76, 1-17.
13. Delescluse, C., Lemaire, G., De Sousa, G., and Rahmani, R. (2000). Is CYP1A1 induction always related to AHR signaling pathway? Toxicology 153, 73-82.
14. Donato, M. T., Gomez-Lechon, M. J., and Castell, J. V. (1993). A microassay for measuring cytochrome P450IA1 and P450IIB1 activities in intact human and rat hepatocytes cultured on 96-well plates. Anal. Biochem. 213, 29-33.
15. Edwards, R. J. (1998). Targeting antipeptide antibodies towards cytochrome P450 enzymes. Methods Mol. Biol. 107, 239-249.
16. Ernst, E. (2001). In The Desktop Guide to Complementary and Alternative Medicine: An Evidence-Based Approach. Mosby, St Louis, MO.
17. Ernst, E. (2004). Kava update: A European perspective. N. Z. Med J. 117, 1205.
18. Fu, P. P., Xia, Q., Guo, L., Yu, H., and Chan, P. C. (2008). Toxicity of kava kava. J. Environ. Sci. Health C Environ. Carcinog. Ecotoxicol. Rev. 26, 89-112.
19. Fugh-Berman, A. (2000). Herb-drug interactions. Lancet 355, 134-138.
20. Gautz, L. D., Kaufusi, P., Jackson, M. C., Bittenbender, H. C., and Tang, C. S. (2006). Determination of kavalactones in dried kava (Piper methysticum) powder using near-infrared reflectance spectroscopy and partial least-squares regression. J. Agric. Food Chem. 54, 6147-6152.
21. Guo, L., Mei, N., Dial, S., Fuscoe, J., and Chen, T. (2007). Comparison of gene expression profiles altered by comfrey and riddelliine in rat liver. BMC Bioinformatics 8(Suppl. 7), S22.
22. Guo, L., Shi, Q., Fang, J. L., Mei, N., Ali, A. A., Lewis, S. M., Leakey, J. E., and Frankos, V. H. (2008). Review of usnic acid and Usnea barbata toxicity. J. Environ. Sci. Health C Environ. Carcinog. Ecotoxicol. Rev. 26, 317-338.
23. Guo, L., Li, Q., Xia, Q., Dial, S., Chan, P. C., and Fu, P. P. (2009). Analysis of gene expression changes of drug metabolizing enzymes in the livers of F344 rats following oral treatment with kava extract. Food Chem. Toxicol. 47, 433-442.
24. Guo, L., Mei, N., Xia, Q., Chen, T., Chan, P. C., and Fu, P. P. (2010a). Gene expression profiling as an initial approach for mechanistic studies of toxicity and tumorigenicity of herbal plants and herbal dietary supplements. J. Environ. Sci. Health C Environ. Carcinog. Ecotoxicol. Rev. 28, 60-87.
25. Guo, L., Shi, Q., Dial, S., Xia, Q., Mei, N., Li, Q. Z., Chan, P. C., and Fu, P. P. (2010b). Gene expression profiling in male B6C3F1 mouse livers exposed to kava identifies-changes in drug metabolizing genes and potential mechanisms linked to kava toxicity. Food Chem. Toxicol. 48, 686-696.
26. Gurley, B. J., Gardner, S. F., Hubbard, M. A., Williams, D. K., Gentry, W. B., Khan, I. A., and Shah, A. (2005). In vivo effects of goldenseal, kava kava, black cohosh, and valerian on human cytochrome P450 1A2, 2D6, 2E1, and 3A4/5 phenotypes. Clin. Pharmacol. Ther. 77, 415-426.
27. Gurley, B. J., Swain, A., Hubbard, M. A., Hartsfield, F., Thaden, J., Williams, D. K., Gentry, W. B., and Tong, Y. (2008). Supplementation with goldenseal (Hydrastis canadensis), but not kava kava (Piper methysticum), inhibits human CYP3A activity in vivo. Clin. Pharmacol. Ther. 83, 61-69.
28. Hu, Z., Yang, X., Ho, P. C., Chan, S. Y., Heng, P. W., Chan, E., Duan, W., Koh, H. L., and Zhou, S. (2005). Herb-drug interactions: A literature review. Drugs 65, 1239-1282.
29. Jain, A. N. (2003). Surflex: Fully automatic flexible molecular docking using a molecular similarity-based search engine. J. Med. Chem. 46, 499-511.
30. Jain, A. N. (2007). Surflex-Dock 2.1: Robust performance from ligand energetic modeling, ring flexibility, and knowledge-based search. J. Comput. Aided Mol. Des. 21, 281-306.
31. Jamieson, D. D., and Duffield, P. H. (1990). The antinociceptive actions of kava components in mice. Clin. Exp. Pharmacol. Physiol. 17, 495-507.
32. Jiang, T. F., Wang, Y. H., Lv, Z. H., and Yue, M. E. (2007). Determination of kava lactones and flavonoid glycoside in Scorzonera austriaca by capillary zone electrophoresis. J. Pharm. Biomed. Anal. 43, 854-858.
33. Kilham, C. (1996). Kava: Medicine Hunting in Paradise. Park Street Press, Rochester VT.
34. Koh, H. L., and Woo, S. O. (2000). Chinese proprietary medicine in Singapore: Regulatory control of toxic heavy metals and undeclared drugs. Drug Saf. 23, 351-362.
35. Lee, J. E., and Safe, S. (2000). 3',4'-dimethoxyflavone as an aryl hydrocarbon receptor antagonist in human breast cancer cells. Toxicol. Sci. 58, 235-242.
36. Ma, Q. (2001). Induction of CYP1A1. The AhR/DRE paradigm: Transcription, receptor regulation, and expanding biological roles. Curr. Drug Metab. 2, 149-164.
37. Ma, Y., Sachdeva, K., Liu, J., Ford, M., Yang, D., Khan, I. A., Chichester, C. O., and Yan, B. (2004). Desmethoxyyangonin and dihydromethysticin are two major pharmacological kavalactones with marked activity on the induction of CYP3A23. Drug Metab. Dispos. 32, 1317-1324.
38. Mathews, J. M., Etheridge, A. S., and Black, S. R. (2002). Inhibition of human cytochrome P450 activities by kava extract and kavalactones. Drug Metab. Dispos. 30, 1153-1157.
39. Mathews, J. M., Etheridge, A. S., Valentine, J. L., Black, S. R., Coleman, D. P., Patel, P., So, J., and Burka, L. T. (2005). Pharmacokinetics and disposition of the kavalactone kawain: Interaction with kava extract and kavalactones in vivo and in vitro. Drug Metab. Dispos. 33, 1555-1563.
40. Mei, N., Guo, L., Fu, P. P., Heflich, R. H., and Chen, T. (2005). Mutagenicity of comfrey (Symphytum Officinale) in rat liver. Br. J. Cancer 92, 873-875.
41. Mei, N., Guo, L., Zhang, L., Shi, L., Sun, Y. A., Fung, C., Moland, C. L., Dial, S. L., Fuscoe, J. C., and Chen, T. (2006). Analysis of gene expression changes in relation to toxicity and tumorigenesis in the livers of Big Blue transgenic rats fed comfrey (Symphytum officinale). BMC Bioinformatics 7(Suppl. 2), S16.
42. Miller, E. C., and Miller, J. A. (1981). Mechanisms of chemical carcinogenesis. Cancer 47, 1055-1064.
43. Nelson, L., and Perrone, J. (2000). Herbal and alternative medicine. Emerg. Med. Clin. North Am. 18, 709-722.
44. Nerurkar, P. V., Dragull, K., and Tang, C. S. (2004). In vitro toxicity of kava alkaloid, pipermethystine, in HepG2 cells compared to kavalactones. Toxicol. Sci. 79, 106-111.
45. NTP. (2011). NTP Technical Report on Toxicology and Carcinogenesis Studies of Kava Kava Extract in F344/N Rats and B6C3F1 Mice. NTP TR 571, NIH Publication No.11-5913, National Toxicology Program, Research Triangle Park, NC.
46. Olsen, L. R., Grillo, M. P., and Skonberg, C. (2011). Constituents in kava extracts potentially involved in hepatotoxicity: A review. Chem. Res. Toxicol. 24, 992-1002.
47. Pandini, A., Denison, M. S., Song, Y., Soshilov, A. A., and Bonati, L. (2007). Structural and functional characterization of the aryl hydrocarbon receptor ligand binding domain by homology modeling and mutational analysis. Biochemistry 46, 696-708.
48. Phillips, D. H. (1983). Fifty years of benzo(a)pyrene. Nature 303, 468-472.
49. Pittler, M. H., and Ernst, E. (2003). Kava extract for treating anxiety. Cochrane Database Syst. Rev. 1, CD003383.
50. Rajaraman, G., Yang, G., Chen, J., and Chang, T. K. (2009). Modulation of CYP1B1 and CYP1A1 gene expression and activation of aryl hydrocarbon receptor by Ginkgo biloba extract in MCF-10A human mammary epithelial cells. Can. J. Physiol. Pharmacol. 87, 674-683.
51. Raucy, J. L. (2003). Regulation of CYP3A4 expression in human hepatocytes by pharmaceuticals and natural products. Drug Metab. Dispos. 31, 533-539.
52. Ryu, D. Y., Levi, P. E., and Hodgson, E. (1995). Regulation of cytochrome P-450 isozymes CYP1A1, CYP1A2 and CYP2B10 by three benzodioxole compounds. Chem. Biol. Interact. 96, 235-247.
53. Sali, A., and Blundell, T. L. (1993). Comparative protein modelling by satisfaction of spatial restraints. J. Mol. Biol. 234, 779-779.
54. Sali, A., and Overington, J. P. (1994). Derivation of rules for comparative protein modeling from a database of protein structure alignments. Protein Sci. 3, 1582-1596.
55. Shimada, T., Yamazaki, H., Mimura, M., Wakamiya, N., Ueng, Y. F., Guengerich, F. P., and Inui, Y. (1996). Characterization of microsomal cytochrome P450 enzymes involved in the oxidation of xenobiotic chemicals in human fetal liver and adult lungs. Drug Metab. Dispos. 24, 515-522.
56. Singh, Y. N. (2004). Pharmacology and toxicology of kava and kavalactones. In Kava: From Ethnology to Pharmacology (Y. N. Singh, Ed.). CRC, Boca Raton, FL.
57. Singh, Y. N., and Singh, N. N. (2002). Therapeutic potential of kava in the treatment of anxiety disorders. CNS Drugs 16, 731-743.
58. Spink, B. C., Bennett, J. A., Pentecost, B. T., Lostritto, N., Englert, N. A., Benn, G. K., Goodenough, A. K., Turesky, R. J., and Spink, D. C. (2009). Long-term estrogen exposure promotes carcinogen bioactivation, induces persistent changes in gene expression, and enhances the tumorigenicity of MCF-7 human breast cancer cells. Toxicol. Appl. Pharmacol. 240, 355-366.
59. Su, D., and Li, L. (2011). Trends in the use of complementary and alternative medicine in the United States: 2002-2007. J. Health Care Poor Underserved 22, 296-310.
60. Tang, J., Dunlop, R. A., Rowe, A., Rodgers, K. J., and Ramzan, I. (2011). Kavalactones Yangonin and Methysticin induce apoptosis in human hepatocytes (HepG2) in vitro. Phytother. Res. 25, 417-423.
61. Unger, M., Holzgrabe, U., Jacobsen, W., Cummins, C., and Benet, L. Z. (2002). Inhibition of cytochrome P450 3A4 by extracts and kavalactones of Piper methysticum (Kava-Kava). Planta Med. 68, 1055-1058.
62. Vecchini, F., Lenoir-Viale, M. C., Cathelineau, C., Magdalou, J., Bernard, B. A., and Shroot, B. (1994). Presence of a retinoid responsive element in the promoter region of the human cytochrome P4501A1 gene. Biochem. Biophys. Res. Commun. 201, 1205-1212.
63. Vecchini, F., Mace, K., Magdalou, J., Mahe, Y., Bernard, B. A., and Shroot, B. (1995). Constitutive and inducible expression of drug metabolizing enzymes in cultured human keratinocytes. Br. J. Dermatol. 132, 14-21.
64. Volz, H. P., and Kieser, M. (1997). Kava-kava extract WS 1490 versus placebo in anxiety disorders-a randomized placebo-controlled 25-week outpatient trial. Pharmacopsychiatry 30, 1-5.
65. Whitlock, J. P., Jr. (1999). Induction of cytochrome P4501A1. Annu. Rev. Pharmacol. Toxicol. 39, 103-125.
66. Wu, D., Yu, L., Nair, M. G., DeWitt, D. L., and Ramsewak, R. S. (2002). Cyclooxygenase enzyme inhibitory compounds with antioxidant activities from Piper methysticum (kava kava) roots. Phytomedicine 9, 41-47.
67. Yamazaki, Y., Hashida, H., Arita, A., Hamaguchi, K., and Shimura, F. (2008). High dose of commercial products of kava (Piper methysticum) markedly enhanced hepatic cytochrome P450 1A1 mRNA expression with liver enlargement in rats. Food Chem. Toxicol. 46, 3732-3738.
68. Yang, X. X., Hu, Z. P., Duan, W., Zhu, Y. Z., and Zhou, S. F. (2006). Drugherb interactions: Eliminating toxicity with hard drug design. Curr. Pharm. Des. 12, 4649-4664.
69. Yueh, M. F., Kawahara, M., and Raucy, J. (2005). Cell-based high-throughput bioassays to assess induction and inhibition of CYP1A enzymes. Toxicol. In Vitro 19, 275-287.
70. Zhou, P., Gross, S., Liu, J. H., Yu, B. Y., Feng, L. L., Nolta, J., Sharma, V., Piwnica-Worms, D., and Qiu, S. X. (2010). Flavokawain B, the hepatotoxic constituent from kava root, induces GSH-sensitive oxidative stress through modulation of IKK/NF-B and MAPK signaling pathways. FASEB J. 24, 4722.
71. Zou, L., Harkey, M. R., and Henderson, G. L. (2002). Effects of herbal components on cDNA-expressed cytochrome P450 enzyme catalytic activity. Life Sci. 71, 1579-1589.